News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GeoPharma, Inc. (GORX) Appoints 15-Year Industry Veteran President Of Belcher Pharmaceuticals, Inc. (GORX) Subsidiary

2/9/2006 10:36:07 AM

LARGO, Fla., Feb. 9 /PRNewswire-FirstCall/ -- GeoPharma, Inc. announced today that it has appointed Joseph Mastronardy, Ph.D., President of its wholly owned subsidiary, Belcher Pharmaceuticals, Inc. Dr. Mastronardy will direct all pharmaceutical activities for Belcher's Florida and Maryland facilities, including manufacturing operations and regulatory approvals.

Dr. Mastronardy was most recently a regulatory consultant specializing in application reviews, GMP training, validity audits, problem solving for quality and regulatory control issues, and preparing FDA correspondence and meeting strategies. With more than 15 years of experience in the regulated drug industry, he has held positions in quality assurance, quality control, and regulatory affairs at several drug companies including Sano Corporation, Baker Norton Pharmaceutical Company (a division of IVAX Corporation), Pennex Laboratories and Westward Pharmaceutical Corporation. His responsibilities have included product engineering documents, GMP training, product reviews and investigations and FDA-483 responses. Dr. Mastronardy enhanced his regulatory knowledge and skills as a consumer safety officer in the Office of Generic Drugs at the Food and Drug Administration (FDA) from 1991 to 1993 and was a recipient of an FDA Commendable Service Award.

Dr. Mastronardy is a graduate of Philadelphia College of Pharmacy and Science, the University of Arizona, and a postdoctoral fellow at the Waksman Institute of Rutgers University. He has held memberships in the Regulatory Affairs Professional Society (RAPS) executive committee, is a former chairman for the Regulatory Science Section of the American Association of Pharmaceutical Scientists (AAPS) and is a faculty member for several courses presented annually by the Center for Professional Advancement (CfPA).

Mihir Taneja, chief executive officer of GeoPharma, Inc., commented: "We welcome Dr. Mastronardy to the team and look forward to benefiting from his extensive experience in regulatory affairs, product development and manufacturing and quality assurance."

About Belcher Pharmaceuticals

Belcher Pharmaceuticals, Inc. is a wholly owned subsidiary of GeoPharma, Inc. that develops, manufactures, markets and distributes brand-equivalent prescription and over-the-counter products. The Company has manufacturing facilities outside of Tampa, Florida and in Baltimore, Maryland.

About GeoPharma

GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at , and .

This press release may contain statements that constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

GeoPharma, Inc.

CONTACT: Carol Dore-Falcone, VP and CFO of GeoPharma, +1-727-544-8866,ext. 244, or; or Investor and Media Relations, RachelLevine, The Global Consulting Group, +1-646-284-9439, or,for GeoPharma

Read at

comments powered by Disqus